MK-3475 and Hypofractionated Stereotactic Radiation Therapy in Patients With Non-Small Cell Lung Cancer (NSCLC)
Status:
Recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose of
the combination of Keytruda (pembrolizumab, also called MK-3475) and radiation therapy
(either conventional or stereotactic body radiation therapy [SBRT]). The safety of this
combination will also be studied.
The goal of Phase 2 of this study is to learn if this combination therapy can help to
control metastatic NSCLC.